Radiopharmaceutical biotech company Actithera has appointed Darshan Dalal as Chief Medical Officer. 

Dalal will lead the clinical strategy and build the clinical development organisation as Actithera advances its lead fibroblast activation protein (FAP)-targeting RLT into the clinic. The company is also building its pipeline of differentiated precision-engineered radiopharmaceuticals. 

Dalal joins Actithera with over 15 years of global leadership in oncology and haematology. He has previously advanced more than 10 radioligands in various stages of development ranging from preclinical through to Phase III. 

Before joining Actithera, Dalal held leadership roles at AstraZeneca and Novartis, where he led global teams with full end-to-end development accountability of multiple radioligands, including a key role in the development of Pluvicto, one of the field’s most successful RLTs.  

“Actithera has built a truly differentiated platform grounded in rigorous medicinal chemistry, giving rise to radioligand therapies with the potential for superior binding, tumour retention, selectivity and therapeutic index,” said Dalal. 

“I am excited to join the company at this critical inflection point and to work alongside this talented team as we shape a robust clinical development strategy and advance a pipeline of assets designed to transform clinical outcomes and improve lives.” 

“Darshan’s appointment marks an important milestone for Actithera,” added Dr Andreas Goutopoulos, Chief Executive Officer of Actithera. 

“His track record in progressing radioligand assets from concept to late-stage development aligns perfectly with our ambition to rapidly advance our FAP-targeting and other pipeline assets into the clinic.  

“Darshan’s expertise will strengthen our execution as we build on the momentum of our Series A and enter our next phase of growth.” 

 

Bruno Quinney, Content Team, DDW